The impact of new technologies on vaccines

National Medical Journal of India

Volumn 12, Issue 6, 1999, Pages 274-280

  Talwar, G P ^a   Diwan, Manish ^a   Razvi, Fareha ^a   Malhotra, Ritu ^a  

^a Talwar Research Foundation   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; CHOLERA VACCINE; DIPHTHERIA VACCINE; DNA VACCINE; HEPATITIS B VACCINE; HERPES VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME; MALARIA VACCINE; MICROSPHERE; MONOCLONAL ANTIBODY; POLIOMYELITIS VACCINE; RABIES VACCINE; RECOMBINANT VACCINE; TETANUS TOXOID; TYPHOID VACCINE; VACCINIA VACCINE; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGY; BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; HUMAN; IMMUNIZATION; INFECTION CONTROL; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; REVIEW; RHEUMATOID ARTHRITIS; VACCINATION; VIRUS INFECTION;

ANIMALS; BIOTECHNOLOGY; CANCER VACCINES; CHOLERA VACCINES; HUMANS; IMMUNIZATION PROGRAMS; MICE; TYPHOID-PARATYPHOID VACCINES; VACCINES; VACCINES, COMBINED; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0033384166     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Stoute JA, Slaoui M, Heppner DG, Monin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997;336:86-91.
2. Singh IG, Mukherjee R, Talwar GP. Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium W. Vaccine 1991;9: 10-14.
3. Talwar GP. An immunotherapeutic vaccine for multibacillary leprosy. Intern Rev Immuno 1999;18:229-49.
4. Tyagi AK. Recombinant BCG: An approach to develop vaccines against microbial infections. Immunologist 1998;Suppl 1:589.
5. Germanier R, Cryz SJ Jr. Attenuated oral typhoid vaccine Ty 21a. In: Talwar GP (ed). Progress in immunology vol. (2), New York:Springer-Verlag, 1989:113-7.
6. Holmgren J, Svennerholm AM, Lvnnroth I, Fall-Persson M, Markman B, Lundbeck H. Development of improved cholera vaccine based on subunit toxoid. Nature 1977; 269:602-4.
7. Clemens JD, Sack DA, Harris JR, Chakrabarty J, Khan MR, Stanton BF, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986;2:124-7.
8. Thugapatra M, Sharma C, Gupta N, Ghosh RK, Mukhopadhyay A, Kole H, et al. Construction of a cholera vaccine prototype from a non-toxigenic strain of V. cholerae. Immunologist 1998;Suppl 1:422.
9. Michel ML, Mancini M, Borgone SL, Riviere Y, Tiollais P. DNA immunization to hepatitis B surface Ag (HBsAg) as an approach to prevention for hepatitis B. Immunologist 1998;Suppl 1:47.
10. Panda SK, Nanda SK, Zafrullah M, Ansari IH, Ozdener MH, Jameel S. An Indian strain of hepatitis E virus (HEV): Cloning, sequence, and expression of structural region and antibody responses in sera from individuals from an area of high-level HEV endemicity. J Clin Microbiol 1995;33:2653-9.
11. Sarin SK, Guptan RC, Thakur N, Saigal S, Das BC, Malhotra V. Hepatocellular carcinoma in India: An analysis of possible etiological factors. Immunologist 1998; Suppl 1:427.
12. Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 1983;25:21-8.
13. Lathe R, Kieny MP, Lecocq JP. Immunization against rabies using a vaccinia-rabies recombinant virus expressing the surface glycoprotein. In: Lerner RA, Chamock RM, Brown F (eds). Vaccines, 85. New York:Cold Spring Harbor Laboratory, 1985:157-62.
14. Giavedoni L, Jones L, Mebus C, Yilma T. A vaccinia virus double recombinant expressing F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proc Natl Acad Sci 1991;88:8011-15.
15. Yilma T. Recombinant vaccines and rapid diagnostic kits: Transfer of technologies to developing countries. In: Talwar GP (ed). Recombinant and synthetic vaccines. New Delhi:Narosa Publishing House, 1994:3-14.
16. Srinivasan J, Singh O, Chakrabarti S, Talwar GP. Targeting vaccinia virus-expressed secretory beta subunit of human chorionic gonadotropin (hCG) to the cell surface induces antibodies. Infect Immun 1995;63:4907-11.
17. Srinivasan J, Singh O, Pal R, Lall L, Chakrabarti S, Talwar GP. A recombinant anti-fertility vaccine. In: Griffin PD, Johnson PM (eds). Local immunity in reproductive tract tissues. New Delhi:Oxford University Press, 1993:477-81.
18. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, et al. Immune response to human immunodeficiency virus (HIV) type 1 induced by canary pox expressing HIV-1MN gp 120, HIV-1SF2 recombinant gp 120 or both vaccines in seronegative adults. NLAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-16.
19. Gupta A, Chandershekhar S, Pal R, Talwar GP, Singh O. Identification of novel transmembrane gene sequence and its use for cell surface targeting of beta subunit of human chorionic gonadotropin. DNA Cell Biol 1998;17:573-81.
20. Curtiss R III, Hassan JO, Herr J, Kelly SM, Levine M, Mahairas Milich D, et al. Non-recombinant and recombinant avirulent Salmonella vaccines. In: Talwar GP, Rao KVS, Chauhan VS (eds).Non-recombinant and synthetic vaccines. New Delhi:Narosa Publishing House, 1994:340-51.
21. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-82.
22. Davis HL. Plasmid DNA expression systems for the purpose of immunization. Curr Opin Biotechnol 1997;8:635-40.
23. Wang B, Boyer J, Srikantan V, Ugen K, Gilbert L, Phan C, et al. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates. Virology 1995;211:102-12.
24. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
25. Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P. Immunisation against hepatitis B in man. Lancet 1976;1:1367-70.
26. Lodmell DL, Ray NB, Parnell MJ, Ewalt LC, Hanlon CA, Shaddock JH, et al. DNA immunization protects nonhuman primates against rabies virus. Nat Med 1998;8: 949-52.
27. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2:893-8.
28. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998b;282:476-80.
29. Leitner WW, Seguin MC, Ballou WR, Seitz JP, Schultz AM, Sheehy MJ, et al. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol 1997;159:6112-19.
30. Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Chohen A, et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin Immunol 1999;90:100-7.
31. Raman G. Procedes pour accroitre la production des antioxines. Ann Inst Pasteur 1926;40:1-10.
32. Glenny AT, Pope CG, Waddington H, Wallace U. The antigenic value of the toxin-antitoxin precipitates of Raman. J Path Bacteriol 1926;29:31-42.
33. Zonneveld GM, Crommelin DJA. Liposomes as drug carriers. In: Gregoriadis G (ed). Recent trends and progress, UK:Chichester Wiley, 1988:795.
34. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974; 252:252.
35. Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods 1991;140:1-13.
36. Gregoriadis G, Davis D, Davies A. Liposomes as immunological adjuvants: Antigen incorporation studies. Vaccine 1987;5:145-51.
37. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M, et al. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc Natl Acad Sci USA 1992;89:358-62.
38. Gupta RK, Griffin P, Chang AC, Rivera A, Anderson R, Rost B, et al. The role of adjuvants and delivery systems in modulation of immune responses to vaccines. In: Cohen S, Shafferman A (eds).Novel strategies in design and production of vaccines. New York:Plenum Press, 1996:105-13.
39. Bloom BR. Vaccines for the Third World. Nature 1989;342:115-20.
40. Freund J. The mode of action of immunological adjuvants. Adv Tuberc Res 1956;7: 130-48.
41. Preis I, Langer RS. A single step immunization by sustained antigen release. J Immunol Methods 1979;28:193-7.
42. Kessler DA. The basis of the FDA's decision on breast implants. N Engl J Med 1992;326:1713-15.
43. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argenitieri GJ. Biodegradation of and tissue reaction to 50:50 poly (DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res 1985;19:349-65.
44. Cleland JL, Lim A, Daugherty A, Barron L, Desjardin N, Duenas ET, et al. Development of a single-shot subunit vaccine for HIV-1.5. programmable in vivo autoboost and long lasting neutralizing response. J Pharm Sci 1998;87:1489-95.
45. Kersten GF, Donders D, Akkermans A, Beuvery EC. Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen. Vaccine 1996;14:1627-32.
46. Diwan M, Dawar H, Talwar GP. Induction of early and bioeffective antibody response in rodents with the luteinizing-hormone-releasing hormone vaccine given as a single dose in biodegradable microspheres along with alum. Prostate 1998;35: 279-84.
47. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches.J Control Rel 1990;11:205-14.
48. Yan C, Rill WL, Malli R, Hewetson J, Naseem H, Tammariello R, et al. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 1996;14:1031-8.
49. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins of enveloped viruses. Nature 1984;308:457-69.
50. Osterhaus A, Weijer K, Uytdehaag F, Jarrett O, Sundquist B, Morein B. Induction of protective immune response in cats by vaccination with feline leukaemia virus ISCOM. J Immunol 1985;135:591-6.
51. Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-keyhole limpet hemocyaninplus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999;5:77-81.
52. Zhang H, Zhang S, Cheung NK, Raghupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 1998;58:2844-9.
53. Weynants P, Marchandise FX, Sibille Y. Pulmonary perspective: Immunology in diagnosis and treatment of lung cancer. Eur Respir J 1997;10:2189.
54. Fischer R, Drossard J, Emans N, Commandeur U, Hellwig S. Towards molecular farming in the future: Moving from diagnostic protein and antibody production in microbes to plants. Biotechnol Appl Biochem 1999;30:101-8.
55. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 1998;4:601-6.
56. Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997;9:805-13.
57. Akatsu I, Kojima T, Kariyone A, Fukuda T, Makino S, Takatsu K. Antibody against interleukin-5 prevents antigen induced eosinophil infiltration and bronchial hyperreactivity in the guinea pig airways. Immunol Lett 1995;45:109-16.
58. Ozaki S, Kosaka M, Wakahara Y, Ozaki Y, Tsuchiya M, Koishihara Y, et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999;93:3922-30.
59. Feldman M, Brennan FM, Paleolog P, Taylor P, Maini RN. Anti TNFα antibody (cA2) therapy in rheumatoid arthritis: Rationale, clinical results and mechanism. Immunologist 1998;Suppl 1:12.
60. Shetye J, Ragnhammar P, Liljefors M, Christensson B, Frodin JE, Biberfeld P,et al. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1998;4:1921-9.
61. Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch 14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-80.
62. Wang B, Chen YB, Ayalon O, Bender J, Garen A. Human single-chain Fv immuno-conjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proc Natl Acad Sci USA 1999;96:1627-32.
63. Fanger MW, Morganelli PM, Guyre PM. Bispecific antibodies. Crit Rev Immunol 1992;12:101-24.
64. Sercarz EE, Lehmann PV, Ametani Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants.Annu Rev Immunol 1993;11:729-66.
65. Melief CJM, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995;145:167-77.
66. Melief CJM, Offringa R, Toes RE, Kast WM. Peptide-based cancer vaccines. Curr Opin Immunol 1996;8:651-7.
67. Boon T, Lucas S. Rejection antigens of tumours and specific immunotherapy of cancer. Bull Mem Acad R Med Belg 1996;151:469-79.
68. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. J Immunol 1997;159:3113-7.
69. Gonzalez G, Crombet T, Catala M, Mirabal V, Hernandez JC, Gonzalez Y, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann Oncol 1998;9:431-5.
70. Talwar GP, Choudhuri MK, Jayashankar R. Antigenic derivative of GnRH UK Patent 2228 262, 1992.
71. Gupta HM, Talwar GP, Salunke DM. A novel computer modeling approach to the structures of small bioactive peptides: The structure of gonadotrophin releasing hormone. Proteins 1993;16:48-56.
72. Jayashankar R, Chaudhuri MK, Singh O, Alam A, Talwar GP. Semisynthetic anti-LHRH vaccine causing atrophy of the prostate. Prostate 1989;14:3-11.
73. Giri DK, Chaudhuri M, Jayashankar R, Neelaram G, Jayaraman S, Talwar GP. Histopathological changes in reproductive organs of male wistar rats following active immunization against LHRH. Eur Mol Pathol 1990;52:54-62.
74. Rovan E, Fiebiger E, Kalla NR, Talwar GP, Aulitzky W, Frick J. Effect of active immunization to luteinizing-hormone-releasing hormone on the fertility and histoarchitecture of the reproductive organs of male rat. Urol Res 1992;20:323-34.
75. Talwar GP, Diwan M, Dawar H, Frick J, Sharma SK, Wadhwa SN. Counter GnRH vaccine. Male contraception: Present and future. New Delhi:New Age Publishers, 1999:309-18.